

cancelled claims. Claims 44 and 50 have been amended to recite a method of delivering a therapeutic and to correctly depend on claim 49. Claims 56 and 57 have been added to cover the subject matter in the prior claims numbered as claim 52. At the Examiner's request, new clean copies of the schemes on pages 42, 44, and 48 (as amended in the August 1, 2001 response) are enclosed as Exhibit B.


Applicants respectfully request reconsideration of the subject application in view of the August 1, 2001 Response and this Supplemental Response. The subject application is now in condition for allowance and early notice to that effect is respectfully solicited.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By:


Jeffrey A. Lindeman
Reg. No. 34,658

Dated: October 18, 2001

CUSTOMER NO. 009629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036
(202) 467-7747
(202) 467-7176 (Fax)

Exhibit A: Marked-Up Claim Amendments

44. (Amended) A method of delivering a therapeutic [treatment] comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 18.

46. (Amended) A method of delivering a therapeutic agent comprising the steps of:
combining a cyclodextrin copolymer of claims 1, 8, 9, or 10 [, 11, 13, 14 or 15] with a therapeutic agent to form a mixture; and
allowing said mixture to self-assemble to form an associated composition; and
administering a therapeutically effective amount of said associated composition to a subject in need of said therapeutic agent.

48. (Amended) A linear cyclodextrin copolymer of claim 1, 8, 9, or 10[, or 47] wherein said linear cyclodextrin copolymer is water soluble.

50. (Amended) A method of delivering a therapeutic [treatment] comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 49 [48].

56. (New) A therapeutic composition of claim 49, wherein at least one ligand is bound to the linear cyclodextrin copolymer.

57. (New) A method of delivering a therapeutic comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 56.